Literature DB >> 6108517

The contribution of alpha 1-acid glycoprotein, lipoproteins, and albumin to the plasma binding of perazine, amitriptyline, and nortriptyline in healthy man.

M Brinkschulte, U Breyer-Pfaff.   

Abstract

Parameters for the binding of perazine (PER), amitriptyline (AT) and nortriptyline (NT) to plasma and to single plasma proteins were determined by equilibrium dialysis. The highest affinity (K at least 10(5) M-1) and lowest capacity (first site 1 mol/mol) towards all three drugs was exhibited by alpha 1-acid glycoprotein (alpha 1-AGP). From the parameters, alpha 1-AGP was estimated to contribute 43% to total binding of PER and 49 and 31%, respectively, to AT and NT binding in samples with normal protein concentrations. Fractions bound to total lipoproteins would amount to 32% (PER), 40 (AT) and 52% (NT), respectively, while the contribution of albumin would range from 11% (AT) to 25% (PER). The extent of the binding to plasma was compared with that to single proteins and their mixtures. Binding to combinations of alpha 1-AGP, lipoproteins and albumin exceeded that to plasma with PER but not with AT and NT. This leads to the assumption that additional plasma constituents interfere with PER binding.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6108517     DOI: 10.1007/bf00498432

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  22 in total

1.  Factors affecting the binding of tricyclic tranquillizers and antidepressants to human serum albumin.

Authors:  D Sharples
Journal:  J Pharm Pharmacol       Date:  1976-02       Impact factor: 3.765

2.  The interactions of drugs and plasma proteins.

Authors:  A GOLDSTEIN
Journal:  J Pharmacol Exp Ther       Date:  1949-04       Impact factor: 4.030

3.  Plasma protein binding of basic drugs. II. Importance of alpha 1-acid glycoprotein for interindividual variation.

Authors:  K M Piafsky; O Borgå
Journal:  Clin Pharmacol Ther       Date:  1977-11       Impact factor: 6.875

Review 4.  Binding of drugs by albumin and plasma protein.

Authors:  J J Vallner
Journal:  J Pharm Sci       Date:  1977-04       Impact factor: 3.534

5.  Quantitative correlations between albumin binding constants and chromatographic Rm values of phenothiazine derivatives.

Authors:  A Hulshoff; J H Perrin
Journal:  J Med Chem       Date:  1977-03       Impact factor: 7.446

6.  Binding of tricyclic antidepressants and perazine to human plasma. Methodology and findings in normals.

Authors:  M Brinkschulte; U Breyer-Pfaff
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1979-07       Impact factor: 3.000

7.  Binding of quinidine in sera with different levels of triglycerides, cholesterol, and orosomucoid protein.

Authors:  O G Nilsen; P Leren; I Aakesson; S Jacobsen
Journal:  Biochem Pharmacol       Date:  1978-03-15       Impact factor: 5.858

8.  Binding of phenytoin, L-tryptophan and O-methyl red to albumin. Unexpected effect of albumin concentration on the binding of phenytoin and L-tryptophan.

Authors:  C J Bowmer; W E Lindup
Journal:  Biochem Pharmacol       Date:  1978-03-15       Impact factor: 5.858

9.  Plasma protein binding of basic drugs. I. Selective displacement from alpha 1-acid glycoprotein by tris(2-butoxyethyl) phosphate.

Authors:  O Borgå; K M Piafsky; O G Nilsen
Journal:  Clin Pharmacol Ther       Date:  1977-11       Impact factor: 6.875

10.  The influence of increasing albumin concentrations on the determination of the binding of sulfamethoxy-pyridazine to human and bovine serum albumin.

Authors:  H Miese; W E Müller; U Wollert
Journal:  Arch Int Pharmacodyn Ther       Date:  1978-11
View more
  15 in total

1.  Selectivity in the binding of psychotropic drugs to the variants of alpha-1 acid glycoprotein.

Authors:  C B Eap; C Cuendet; P Baumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-02       Impact factor: 3.000

2.  Interindividual differences in the binding of antidepressives to plasma proteins: the role of the variants of alpha 1-acid glycoprotein.

Authors:  D Tinguely; P Baumann; M Conti; M Jonzier-Perey; J Schöpf
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

3.  High-throughput analysis of drug dissociation from serum proteins using affinity silica monoliths.

Authors:  Michelle J Yoo; David S Hage
Journal:  J Sep Sci       Date:  2011-06-10       Impact factor: 3.645

4.  Differential effect of cancer on the serum protein binding to mianserin and imipramine.

Authors:  I Torres; E Suárez; J M Rodríguez-Sasiain; C Aguirre; R Calvo
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1995 Apr-Jun       Impact factor: 2.441

Review 5.  Pharmacokinetic optimisation of tricyclic antidepressant therapy.

Authors:  M Furlanut; P Benetello; E Spina
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

6.  Determination of free fractions of tricyclic antidepressants.

Authors:  G Nyberg; E Mårtensson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-09       Impact factor: 3.000

7.  Plasma protein binding of imipramine in patients with rheumatoid arthritis.

Authors:  C B Kristensen
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

8.  Plasma protein binding of perazine and amitriptyline in psychiatric patients.

Authors:  M Brinkschulte; H J Gaertner; H W Schied; U Breyer-Pfaff
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

9.  Lack of accumulation of midazolam in plasma and lipoprotein fractions during intravenous lipid infusions in patients on artificial respiration.

Authors:  I Walter-Sack; J X de Vries; J Rudi; R Conradi; M Kohlmeier; B Kohl; E Weber
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

10.  Drug binding in sera deficient in lipoproteins, albumin or orosomucoid.

Authors:  E Pike; P Kierulf; B Skuterud; J E Bredesen; P K Lunde
Journal:  Br J Clin Pharmacol       Date:  1983-09       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.